Results for: oncology+products

Ziopharm takes bigger loss as research costs grow

Chavez back in Venezuela, stirs succession talk

Cold caps tested to prevent hair loss during chemo

Cancer costs EU $170 bln annually

Pfizer earnings drop less than expected

AstraZeneca rejects sweetened Pfizer takeover bid

Pfizer sales way off mark as company pursues AstraZeneca

Roche's $8 billion InterMune buy not a signal for more big deals

Deal fever hits global pharma sector

New breast cancer drugs boost sales at Roche

Google researching use of color in business

Pfizer $33 Billion Question Remains After Teva, Actavis Feelers

Roche Forecasts Higher Earnings as 2014 EPS Misses Estimates

AstraZeneca to carve out antibiotic R&ampD into separate firm

Million dollar deal for cancer research

Ziopharm rises on preclinical cancer therapy study

Stocks gain, pushing the S&P 500 to 5-year high

Obama, UN, US home sales, IPOs, Nike: The week ahead

Pfizer's need for deal looms larger with earnings report

Pfizer's need for deal looms larger with earnings report

Pfizer dampens Astra bid hopes with German Merck cancer deal

AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

GSK to axe U.S. jobs as part of $1.6 billion cost cuts: sources